The Manila Times

Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adul…

(NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative ...